Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3520-3528

  Armeanu, Sorin ^a   Krusch, Matthias ^b   Baltz, Katrin M ^b   Weiss, Thomas S ^c   Smirnow, Irina ^a   Steinle, Alexander ^b   Lauer, Ulrich M ^a   Bitzer, Michael ^a,b   Salih, Helmut R ^b  

^a Departments of Gastroenterology and Hepatology   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CELL SURFACE PROTEIN; GAMMA INTERFERON; MESSENGER RNA; NATURAL KILLER CELL RECEPTOR NKG2D; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; HLA ANTIGEN CLASS 1; MHC CLASS I RELATED CHAIN A; MHC CLASS I-RELATED CHAIN A; MICB ANTIGEN; PYRAZINE DERIVATIVE; SIGNAL PEPTIDE; ULBP2 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IC 50; IMMUNOMODULATION; INTERFERON PRODUCTION; LIVER CELL CARCINOMA; LOW DRUG DOSE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECT; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; LIVER TUMOR; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON TYPE II; KILLER CELLS, NATURAL; LIVER NEOPLASMS; PYRAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 50349102578     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4744     Document Type: Article

References (37)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
2. Burroughs A, Hochhauser D, Meyer T, Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 2004;5:409-18.
3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Che-moembolization improves survival. Hepatology 2003;37:429-42.
4. Butterfield LH, Ribas A. Immunotherapy of hepatocellular carcinoma. Expert Opin Biol Ther 2002;2:123-33
5. Geissler M, Mohr L, Ali MY, Grimm CF, Ritter M, Blum HE. Immunobiology and gene-based immunotherapy of hepatocellular carcinoma. Z Gastroenterol 2003;41:1101 -10.
6. Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 2007;4:424-32
7. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000;356:802-7.
8. Adams J. The proteasome: A suitable antineoplastic target. Nat Rev Cancer 2004;4:349-60.
9. Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007;21:30-6.
10. Koschny R, Ganten TM, Sykora J, et al. TRAIL/bor-tezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 2007;45:649-58.
11. Lauricella M, Emanuele S, DAnneo A, et al. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways. Apoptosis 2006;11:607-25.
12. Markasz L, Stuber G, Vanherberghen B, et al. Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells. Mol Cancer Ther 2007;6:644-54.
13. Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225 - 74.
14. Ishiyama K, Ohdan H, Ohira M, Mitsuta H, Arihiro K. Asahara T. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology 2006;43:362-72.
15. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class l-bearing tumor in vivo. Proc Natl Acad Sci U S A 2001;98:11521-6.
16. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001;413:165-71.
17. Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003;102:1389-96.
18. Pathil A, Armeanu S. Venturelli S, et al. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 2006;43:425-34.
19. Armeanu S, Bitzer M, Lauer UM, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005;65:6321-9.
20. Armeanu S, Pathi A, Venturelli S, et al. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol 2004;42:210-7.
21. Skehan P, Storeng R, Scudiero D, et al. New colori-metric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
22. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-8.
23. Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002;169:4098-102.
24. Calvaruso G, Giuliano M, Portanova P. De Blasio A, Vento R, Tesoriere G. Bortezoi aib induces in HepG2 cells lκBα degradation mediated by caspase-8. Mol Cell Biochem 2006:287:13-9.
25. Ganten TM, Koschny R, Haas TL, et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes. to TRAIL. Hepatology 2005;42:588-97.
26. Leveque D, Maloisel F. Clinical pharmacokinetics of imatinib mesylate. In Vivo 2005;19:77-84.
27. Oppenheim DE, Roberts SJ, Clarke SL. et al Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 2005;6:928-37.
28. Smyth MJ, Swann J, Cretney E, Zerafa N.Yokoyama WM, Hayakawa Y. NKG2D function protects the host from tumor initiation. J Exp Med 2005;202:583-8.
29. Osaki T, Saito H, Yoshikawa T. et al. Decreased NKG2D expression on CD8+ Tcell is involved in immune evasion in patients with gastric cancer Clin Cancer Res 2007;13:382-7.
30. Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 2006;66:2520-6.
31. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003;3:781 -90.
32. Dunn GP. Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting Nat Rev Immunol 2006:6:836-48.
33. Lundqvist A, Abrams SI, Schrump DS, et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 2006;66:7317-25.
34. Lu M, Kitson RP, Xue Y, Goldfarb RH Activation of multiple caspases and modification of cell surface fas (CD95) in proteasome inhibitor-induced apoptosis of rat natural killer cells. J Cell Biochem 2003;88:482 - 92.
35. Schumacher LY Vo DD, Garban HJ, et al. Immuno-sensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol 2006;176:4757-65.
36. Jiang K, Zhong B, Gilvary DL, et al. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat Immunol 2000;1:419 - 25.
37. Lieberman LA. Hunter CA Regulatory pathways involved in the infection-induced production of IFN-γ by NK cells. Microbes Infect 2002:4:1531 -8.